Semaglutide and Tirzepatide are injectable peptides that work by mimicking the body's natural hunger-regulating hormones (GLP-1 and GIP). Originally developed to treat Type 2 diabetes, both medications have become the most clinically validated tools in modern medical weight loss — with patients averaging 15–22% total body weight reduction in clinical trials.
They work by slowing gastric emptying, reducing appetite signaling in the brain, regulating blood sugar, and improving insulin sensitivity — producing meaningful, sustained weight loss without the hunger, misery, or deprivation of traditional dieting.
Semaglutide (Wegovy / Ozempic)
A GLP-1 receptor agonist. Reduces appetite, slows digestion, and regulates blood sugar. Weekly subcutaneous injection. Clinically proven ~15% average weight loss.
Tirzepatide (Mounjaro / Zepbound)
A dual GLP-1 and GIP receptor agonist — the next generation. More powerful appetite suppression and insulin regulation. Clinical trials show up to 22% average weight loss. Weekly subcutaneous injection.
Our providers will help you determine which peptide is right for your metabolic profile, health history, and weight loss goals.
Mardi Gras Wellness offers physician-supervised Semaglutide and Tirzepatide therapy for patients in FL and the surrounding area. Our medical weight loss program begins with a comprehensive evaluation — including lab work, health history, and body composition analysis — to confirm you’re a candidate and determine the right medication and dose.
We don’t just prescribe and disappear. Our team monitors your progress monthly, adjusts your dosage based on response, and provides ongoing support for nutrition, lifestyle, and any side effects that arise.
Medical weight loss at Mardi Gras is not a diet program. It is a clinical intervention designed to correct the hormonal and metabolic imbalances that make sustained weight loss so difficult for so many people. If you’ve been struggling, the problem was never your willpower — it was your biology. We can help you change that.
Semaglutide targets one hormone receptor (GLP-1), while Tirzepatide targets two (GLP-1 and GIP). Tirzepatide is generally more effective for weight loss, with clinical trials showing superior outcomes. Your provider will help you choose based on your history and goals.
Clinical results vary, but patients on Tirzepatide average 20–22% total body weight loss over 72 weeks. Semaglutide patients average approximately 15%. Individual results depend on adherence, lifestyle, and baseline metabolic health.
The most common side effects are mild nausea, constipation, or reduced appetite — most of which resolve as the body adjusts. We use a slow titration schedule to minimize discomfort.
Yes. We require baseline lab work before initiating any GLP-1 therapy. This protects your safety and helps us personalize your dose.
Some weight regain is common after discontinuation. Our team works with you on transition planning, lifestyle anchoring, and maintenance strategies to protect your results long-term.
